State of the Biopharmaceutical Industry 2026 Edition
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
The biopharmaceutical industry is entering 2026 against a backdrop of heightened uncertainty, shaped by macroeconomic volatility, geopolitical tension, regulatory change, and rapid technological evolution. While the sector is often viewed as relatively resilient during economic downturns, it continues to face mounting pressure from pricing and reimbursement constraints, regulatory reform, supply chain disruption, and intensifying demands to innovate sustainably.
At the same time, emerging technologies such as artificial intelligence, automation, and personalized medicine are redefining how biopharmaceutical companies operate across the value chain. These technologies offer pathways to greater efficiency and innovation, but also introduce new complexity as companies balance cost pressures, regulatory scrutiny, and shifting global policy priorities.
GlobalData’s State of the Biopharmaceutical Industry report examines the business environment, trends, and challenges expected to shape the industry over the next 12 months. Drawing on survey data from pharmaceutical professionals, the report provides a grounded, forward-looking view of which themes will have the greatest positive and negative impact on industry performance in 2026.
Scope
This report benchmarks the impact of major themes shaping the biopharmaceutical industry over the next 12 months, including:
Assessment of emerging technologies, regulatory trends, macroeconomic trends, and industry dynamics
Identification of themes expected to have the greatest positive or negative impact
Capture and analysis of expert opinions from pharmaceutical industry professionals
Evaluation of industry growth prospects for the next 12 months
How industry leaders are using this report
Biopharmaceutical executives, strategy teams, and market intelligence professionals use this report to:
- Understand how macroeconomic, regulatory, and technological forces are converging to shape industry performance.
- Assess near-term risks and opportunities linked to pricing, reimbursement, and policy reform.
- Benchmark sentiment and expectations across the global biopharmaceutical industry.
- Inform strategic planning, portfolio decisions, and investment prioritization for 2026.
- Anticipate shifts in funding, collaboration, and geographic investment focus.
Key Highlights
This report highlights the most important trends and sentiment shaping the biopharmaceutical industry outlook, including:
- Artificial intelligence, immuno-oncology, rising clinical trial costs, and personalized and precision medicine rated as the most impactful emerging industry trends for the next 12 months.
- Surveyed pharmaceutical professionals identifying AI across the pharma value chain, delays in revenue generation due to pricing and reimbursement processes, and supply chain challenges as the trends with the greatest industry impact.
- Regulatory and macroeconomic actions linked to the Trump administration ranked as both the most positive and the most negative emerging trend, highlighting deep uncertainty around policy direction.
- Growing pressure on drug pricing from most-favored-nation (MFN) pricing and drug price constraints under the Inflation Reduction Act (IRA).
- Strong belief among respondents that collaboration with China will continue, with many viewing partnerships as an ongoing opportunity.
- 52% of respondents reporting optimistic or very optimistic sentiment about the biopharmaceutical industry’s growth prospects in 2026.
- Improving outlook for biotech funding recovery, with 39% of respondents optimistic or very optimistic for the next 12 months, up from 24% in May 2026.
- Increased competitive pressure from biosimilars, with price linkage requirements expected to reduce prices for both originator products and biosimilars.
- Expectation that the EU and US will attract the most investment in the next 12 months, followed by the EU and China.
- Top-selling drugs for 2026 forecast to include Eli Lilly’s Mounjaro, rising from sixth to third place, and Novo Nordisk’s Wegovy, entering the top 10 at eighth place.
Reasons to Buy
This report enables you to:
- Gain a clear understanding of the business environment facing the biopharmaceutical industry.
- Analyze how major industry, regulatory, and macroeconomic themes will affect the sector in the next 12 months.
- Identify which trends are likely to have the most positive or negative impact in the near term.
- Understand industry sentiment toward growth, funding recovery, and collaboration opportunities.
- Support informed decision-making with data-driven, forward-looking analysis.
Who should buy this report
- Biopharmaceutical and Pharmaceutical Companies
- Biotechnology Firms
- Strategy, Market Intelligence, and Competitive Intelligence Teams
- Regulatory, Market Access, and Policy Teams
- Investors and Corporate Development Teams
- Consultants and Industry Advisors
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports